Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Core Insights - Candel Therapeutics has appointed Dr. Bali Pulendran to its Research Advisory Board, enhancing its expertise in systems immunology and vaccinology as it advances its viral immunotherapy candidates [1][2][3] Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal viral immunotherapies to elicit systemic anti-tumor immune responses [4] - The company has established two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs [4] Product Development - Candel's lead product candidate, CAN-2409, has completed successful phase 2a clinical trials in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [5] - A pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer is underway, conducted under a Special Protocol Assessment (SPA) with the FDA [5] - CAN-2409 has received Fast Track Designation from the FDA for multiple indications, including PDAC and stage III/IV NSCLC [5] - CAN-3110, the lead candidate from the HSV platform, is currently in a phase 1b clinical trial for recurrent high-grade glioma and has also received Fast Track and Orphan Drug Designations from the FDA [6] Research and Development - Dr. Pulendran's expertise is expected to provide valuable insights into the immune system's response to therapies, aiding in the advancement of CAN-2409 and CAN-3110 [2][3] - Candel's enLIGHTEN™ Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors [6]